Description

The global ticagrelor market is poised to grow by US$ 735.0 million from 2022 to 2028, registering a CAGR of 6.8% during the forecast period, according to StrategyHelix.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for ticagrelor. The global ticagrelor market is segmented on the basis of dosage, route of administration, application, end user, and region. By dosage, the global ticagrelor market has been segmented into 90mg, 60mg. Based upon route of administration, the global ticagrelor market is categorized into nasogastric tube, oral. On the basis of application, the global ticagrelor market has been segmented into acute coronary syndrome, cardiac surgery. By end user, the global ticagrelor market has been segmented into ambulatory surgery centers (ASCs), hospitals & clinics, others. In terms of geography, the global ticagrelor market has been segmented into North America, Asia Pacific, Europe, Rest of the World (ROW).

The competitive landscape of the market is highly consolidated and dominated by key players such as AstraZeneca plc.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the ticagrelor market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Dosage: 90mg, 60mg
Route of administration: nasogastric tube, oral
Application: acute coronary syndrome, cardiac surgery
End user: ambulatory surgery centers (ASCs), hospitals & clinics, others
Region: North America, Asia Pacific, Europe, Rest of the World (ROW)
Years considered: this report covers the period 2018 to 2028

Key Benefits for Stakeholders

– Get a comprehensive picture of the global ticagrelor market
– Pinpoint growth sectors and trends for investment

Table of Contents

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Ticagrelor market overview
Part 3. Market breakdown by dosage
– 90mg
– 60mg
Part 4. Market breakdown by route of administration
– Nasogastric tube
– Oral
Part 5. Market breakdown by application
– Acute coronary syndrome
– Cardiac surgery
Part 6. Market breakdown by end user
– Ambulatory surgery centers (ASCs)
– Hospitals & clinics
– Others
Part 7. Market breakdown by region
– North America
– Asia Pacific
– Europe
– Rest of the World (ROW)
Part 8. Key companies
– AstraZeneca plc
About StrategyHelix
Disclaimer